Gossamer Bio/$GOSS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Gossamer Bio
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
- Ticker
- $GOSS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 162
- Headquarters
- San Diego, United States
- Website
- www.gossamerbio.com
Gossamer Bio Metrics
BasicAdvanced
$65M
-
-$51.97
2.00
-
Price and volume
Market cap
$65M
Beta
2
52-week high
$309.60
52-week low
$9.10
Average daily volume
334K
Financial strength
Current ratio
0.528
Quick ratio
0.458
Long term debt to equity
-0.031
Total debt to equity
-0.426
Interest coverage (TTM)
-14.47%
Profitability
EBITDA (TTM)
-158.597
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-235.00%
Operating margin (TTM)
-297.67%
Effective tax rate (TTM)
0.07%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-62.39%
Return on equity (TTM)
178.72%
Valuation
Price to revenue (TTM)
0.637
Price to book
-0.7
Price to tangible book (TTM)
-0.7
Price to free cash flow (TTM)
-0.209
Free cash flow yield (TTM)
-478.93%
Free cash flow per share (TTM)
-51.291
Growth
Revenue change (TTM)
32.43%
Earnings per share change (TTM)
6.17%
3-year earnings per share growth (CAGR)
-33.41%
Gossamer Bio Financial Performance
Revenues and expenses
Gossamer Bio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Gossamer Bio News
AllArticlesVideos
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Business Wire2 weeks ago
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Business Wire3 weeks ago
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Business Wire3 weeks ago
Funds containing Gossamer Bio
AllUSDGBP
Fund name | Fund size | $GOSS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.01% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.